Timolol (Ophthalmic)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Open-angle glaucoma — elevated IOP | Adults and children ≥2 years | Monotherapy or adjunctive | FDA Approved |
| Ocular hypertension — IOP reduction | Adults and children ≥2 years | Monotherapy or adjunctive | FDA Approved |
Timolol was among the first topical beta-blockers approved for glaucoma management (FDA approval 1978) and has been a cornerstone of IOP-lowering therapy for over four decades. While prostaglandin analogues have largely supplanted beta-blockers as preferred first-line monotherapy, timolol remains widely used as a second-line agent or in fixed-dose combination products with prostaglandins, carbonic anhydrase inhibitors, or alpha-agonists. In controlled multiclinic studies, timolol 0.25% or 0.5% administered twice daily produced greater IOP reduction than pilocarpine or epinephrine solutions. The mean resting heart rate reduction observed in pivotal trials was 2.9 beats/minute (SD 10.2), reflecting significant systemic beta-blockade from topical administration.
Infantile haemangioma (topical): Timolol 0.5% gel applied topically 2–3 times daily to thin, superficial infantile haemangiomas. The American Academy of Pediatrics endorses topical timolol as an option for superficial lesions. (Evidence quality: Moderate)
Pediatric glaucoma (<2 years): While FDA labelling supports use in children ≥2 years, timolol is frequently used off-label in younger infants with congenital glaucoma, typically at the 0.25% concentration with nasolacrimal occlusion to minimise systemic effects. (Evidence quality: Low)
Timolol Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Open-angle glaucoma — initial solution therapy | 1 drop 0.25% in affected eye(s) BID | 1 drop 0.25% or 0.5% BID; may reduce to QD if IOP controlled | 1 drop 0.5% BID | Allow ~4 weeks to evaluate full IOP response Higher doses not shown to produce further IOP reduction (FDA PI) |
| Open-angle glaucoma — gel-forming solution (GFS/XE) | 1 drop 0.25% or 0.5% in affected eye(s) QD | Same as starting dose | 1 drop 0.5% QD | Invert bottle and shake once before use; equally effective as solution BID Transient blurred vision common (~33%) on instillation |
| Ocular hypertension — monotherapy | 1 drop 0.25% in affected eye(s) BID | Increase to 0.5% BID if response inadequate; reduce to QD if controlled | 1 drop 0.5% BID | Assess diurnal IOP at multiple time-points before switching to QD Concomitant therapy with other IOP agents may be needed |
| Adjunctive therapy — with prostaglandin analogue or other topical agents | 1 drop 0.25% or 0.5% BID (solution) or QD (GFS) | Same as starting dose | 1 drop 0.5% BID | Administer other topical ophthalmic medications at least 10 minutes before timolol Do NOT combine with another topical beta-blocker |
| Pediatric glaucoma — children ≥2 years | 1 drop 0.25% in affected eye(s) BID | 0.25% or 0.5% BID | 1 drop 0.5% BID | Safety and IOP-lowering established in children ≥2 years Use nasolacrimal occlusion to reduce systemic absorption in paediatric patients |
Approximately 80% of a topically applied timolol eye drop is systemically absorbed, primarily via nasal and pharyngeal mucosal vessels that drain from the nasolacrimal duct. Instructing patients to apply gentle digital pressure over the medial canthus for 1–2 minutes after instillation significantly reduces systemic absorption and the risk of cardiovascular and respiratory adverse effects. This technique is particularly important in elderly patients, those with cardiac or pulmonary comorbidities, and paediatric patients.
Administration Guidance
Remove contact lenses before instillation and wait at least 15 minutes before reinserting. When using other topical ophthalmic drugs, administer them at least 10 minutes before timolol (this is 10 minutes, not 5 minutes as with some other agents). For gel-forming solution (GFS/XE), invert the container and shake once before use. The preserved multi-dose solution (Timoptic) contains benzalkonium chloride 0.01%; the preservative-free single-dose formulation (Timoptic in Ocudose) is available for patients with ocular surface sensitivity. Store at 15–25°C. Protect from freezing and light.
Pharmacology
Mechanism of Action
Timolol maleate is a non-selective beta1 and beta2 adrenergic receptor blocking agent that lacks significant intrinsic sympathomimetic activity, direct myocardial depressant activity, or local anaesthetic (membrane-stabilising) properties. When applied topically to the eye, timolol reduces elevated and normal IOP by decreasing aqueous humour production. Tonography and fluorophotometry studies suggest that its predominant action is related to reduced aqueous formation through blockade of beta-adrenergic receptors on the ciliary epithelium, which decreases cyclic AMP-mediated fluid secretion. Some studies have also demonstrated a modest increase in outflow facility. The onset of IOP reduction typically occurs within 30 minutes of a single dose, with peak effect at 1–2 hours, and clinically significant IOP lowering persisting for up to 24 hours.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | ~78% systemic bioavailability from ophthalmic route; Tmax (plasma) ~15 min; mean Cmax 0.46 ng/mL (morning) and 0.35 ng/mL (afternoon) after 0.5% BID | Substantial systemic absorption underlies the cardiovascular and pulmonary adverse effects; nasolacrimal occlusion reduces systemic exposure |
| Distribution | Vd = 1.3–1.7 L/kg; protein binding ~10% (equilibrium dialysis) or ~60% (ultrafiltration) | Wide distribution into tissues including lung, liver, and kidney; low protein binding means a large fraction of circulating timolol is pharmacologically active |
| Metabolism | Hepatic, primarily via CYP2D6; CYP2C19 minor contributor; extensive first-pass metabolism (oral route) | CYP2D6 poor metabolisers have higher plasma levels and increased risk of systemic adverse effects; CYP2D6 inhibitors (SSRIs, quinidine) can potentiate beta-blockade |
| Elimination | Plasma t½ ~4 hours (range 2.5–5 h; up to 7.5 h in CYP2D6 poor metabolisers); renal excretion of drug and metabolites | Longer half-life than latanoprost (17 min) means sustained systemic beta-blockade; no dose adjustment needed for renal impairment, but timolol is dialysable |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Burning and stinging on instillation | ~12.5% (1 in 8 patients) | Most frequently reported adverse effect for solution; usually transient and self-resolving within seconds |
| Transient blurred vision (GFS only) | ~33% (1 in 3 patients) | Specific to gel-forming solution; lasts 30 seconds to 5 minutes; instruct patients to avoid driving immediately after instillation |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Conjunctival hyperemia | 1–5% | Mild ocular redness; less common than with prostaglandin analogues |
| Foreign body sensation | 1–5% | Typically transient on instillation |
| Ocular discomfort / itching | 1–5% | Mild; may be partly attributable to benzalkonium chloride preservative |
| Tearing | 1–5% | Reflex lacrimation; self-resolving |
| Blepharitis / eyelid crusting | 1–5% | Standard lid hygiene measures usually sufficient |
| Headache | 1–5% | Systemic effect; usually mild and transient |
| Upper respiratory infection | 1–5% | Causal relationship uncertain; reported at similar rates in controlled studies |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Bronchospasm / respiratory failure | Uncommon; potentially fatal | May occur with first dose or at any time | Immediate discontinuation; emergency bronchodilator therapy; contraindicated in asthma and severe COPD; deaths reported (FDA PI) |
| Bradycardia / heart block | Uncommon | Days to weeks; dose-related | Assess heart rate and ECG; discontinue if symptomatic; atropine for severe bradycardia; contraindicated in sinus bradycardia and 2nd/3rd degree AV block |
| Cardiac failure / cardiac arrest | Rare; potentially fatal | Variable; may develop insidiously | Discontinue immediately at first sign of cardiac failure; contraindicated in overt cardiac failure and cardiogenic shock; deaths reported (FDA PI) |
| Hypotension / syncope | Uncommon | Variable | Monitor blood pressure; consider dose reduction or discontinuation; review concurrent antihypertensive and cardioactive medications |
| Depression / CNS effects (confusion, hallucinations, anxiety, memory loss) | Uncommon (postmarketing) | Weeks to months | Discontinue and observe for resolution; symptoms typically reversible on cessation; may progress to catatonia in severe cases |
| Masking of hypoglycaemia | Risk present in all diabetic patients | Any time during therapy | Warn diabetic patients that beta-blockade may mask tachycardia and tremor of hypoglycaemia; monitor glucose more frequently; sweating is not masked |
| Cystoid macular oedema | Rare (postmarketing) | Variable | Ophthalmology assessment; consider discontinuation |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Ocular intolerance (burning, stinging, conjunctivitis) | Most common ophthalmological reason | Primarily reported with preserved formulations; may improve with preservative-free product |
| Systemic effects (cardiovascular / respiratory) | Leading non-ocular reason | Reflects significant systemic absorption; nasolacrimal occlusion and low concentration (0.25%) can mitigate |
Unlike prostaglandin analogues, timolol has clinically significant systemic absorption (~78% bioavailability). The FDA PI carries warnings that the same adverse reactions found with systemic beta-blockers may occur with topical ophthalmic administration, including severe respiratory reactions and cardiac reactions. Deaths due to bronchospasm in patients with asthma and deaths in association with cardiac failure have been reported. These systemic effects distinguish timolol from most other topical glaucoma agents and necessitate thorough systemic screening before initiation.
Drug Interactions
Timolol is metabolised primarily by CYP2D6 and produces clinically relevant systemic beta-blockade from ophthalmic administration. Drug interactions are therefore both metabolic (CYP2D6-mediated) and pharmacodynamic (additive beta-blockade or cardiovascular depression). This interaction profile is substantially broader than that of prostaglandin analogues.
Monitoring
-
Intraocular Pressure
Baseline; then at ~4 weeks; then every 3–6 months
Routine Allow approximately 4 weeks for IOP response to stabilise before dose changes. Measure diurnal IOP at different times of day before switching from BID to QD dosing, as trough IOP control varies. -
Heart Rate & Blood Pressure
Baseline; then each visit; earlier if symptomatic
Routine Assess resting heart rate before and after initiation. Mean HR reduction of 2.9 bpm was observed in pivotal trials, but individual patients may experience clinically significant bradycardia. Recheck if patient reports dizziness, fatigue, or syncope. -
Pulmonary Function
Baseline if respiratory history; as needed
Trigger-based Screen for asthma, COPD, and reactive airway disease before initiating. Timolol is absolutely contraindicated in asthma and severe COPD. If any new respiratory symptoms (wheezing, dyspnoea, cough) develop, consider immediate discontinuation. -
Blood Glucose (Diabetic Patients)
As per diabetes management plan; more frequently at initiation
Trigger-based Beta-blockers may mask tachycardia and tremor associated with hypoglycaemia. Sweating is not masked. Counsel diabetic patients about this effect and ensure adequate glucose monitoring is in place. -
Mood & CNS Symptoms
Each visit; patient self-report
Routine Ask about depression, fatigue, insomnia, nightmares, confusion, and memory difficulties. Systemic beta-blockers are associated with CNS depression; some patients may not spontaneously report these symptoms. Usually reversible on discontinuation. -
Visual Fields
Per glaucoma guidelines (every 6–12 months)
Routine Standard automated perimetry to detect glaucomatous progression. Not specific to timolol but essential for overall glaucoma management.
Contraindications & Cautions
Absolute Contraindications
- Bronchial asthma or history of bronchial asthma — risk of fatal bronchospasm (FDA PI Section 4)
- Severe chronic obstructive pulmonary disease (FDA PI Section 4)
- Sinus bradycardia (FDA PI Section 4)
- Second or third degree atrioventricular block (FDA PI Section 4)
- Overt cardiac failure (FDA PI Section 4)
- Cardiogenic shock (FDA PI Section 4)
- Hypersensitivity to timolol maleate or any component of the product (FDA PI Section 4)
Relative Contraindications (Specialist Input Recommended)
- Mild-to-moderate COPD or history of bronchospastic disease (other than asthma) — should generally not receive beta-blockers; if essential, use lowest concentration with careful monitoring
- Compensated heart failure — continued myocardial depression may precipitate overt failure
- Patients scheduled for major surgery — beta-blockade may impair cardiac response to reflex stimuli; discuss with anaesthetist
- Pregnancy — no adequate studies; use only if benefit clearly justifies risk; systemic absorption is substantial
Use with Caution
- Diabetes mellitus — may mask signs of hypoglycaemia (tachycardia, tremor); counsel patient
- Thyrotoxicosis — may mask clinical signs (tachycardia); abrupt withdrawal might precipitate thyroid storm
- Myasthenia gravis — beta-blockade may potentiate muscle weakness, ptosis, and diplopia
- Cerebrovascular insufficiency — potential effects on blood pressure and pulse may reduce cerebral blood flow
- Atopic patients or history of severe anaphylaxis — may be more reactive to allergen challenge and less responsive to epinephrine
- Angle-closure glaucoma — timolol has no effect on pupil size; must not be used alone (requires miotic co-therapy to reopen the angle)
- Contact lens wearers — remove before instillation; reinsert after 15 minutes; benzalkonium chloride may be absorbed by soft lenses
The FDA-approved labelling for timolol ophthalmic products contains prominent warnings that the same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical ophthalmic administration. Severe respiratory reactions including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported. These risks are unique among topical glaucoma agents and require comprehensive cardiovascular and respiratory screening before prescribing. Patients should be instructed to report any respiratory difficulty, chest pain, or unusual fatigue immediately.
Patient Counselling
Purpose of Therapy
Timolol eye drops are prescribed to lower the pressure inside the eye, which protects the optic nerve and helps prevent vision loss from glaucoma. The medication controls the condition but does not cure it, and it must be used consistently even if you feel well. Do not stop using timolol without speaking to your eye doctor, as the pressure may rise again.
How to Take
For the regular solution, instil one drop into the affected eye(s) as directed (usually twice daily). For the gel-forming solution, instil once daily after inverting the bottle and shaking once. Apply gentle pressure with a fingertip over the inner corner of the eye (near the nose) for 1–2 minutes after instilling the drop to reduce absorption into the bloodstream. If using other eye drops, wait at least 10 minutes between each. Remove contact lenses before use and wait 15 minutes before reinserting.
Sources
- Timoptic (timolol maleate ophthalmic solution) 0.25% and 0.5% — Full Prescribing Information (Bausch + Lomb). NDA 18086/S-076, revised April 2016. accessdata.fda.gov Primary source for all FDA-approved indications, dosing, contraindications, adverse reactions, and pharmacokinetic data used in this monograph.
- Timolol GFS (timolol maleate ophthalmic gel forming solution) 0.25% and 0.5% — Full Prescribing Information (Sandoz). NDA 020963/S-015, 2024. accessdata.fda.gov Gel-forming solution PI; provides once-daily dosing data, paediatric safety information from 3-month trial, and GFS-specific adverse event rates (blurred vision ~33%).
- Timoptic in Ocudose (timolol maleate ophthalmic solution, preservative-free) 0.25% and 0.5% — Full Prescribing Information (Bausch + Lomb). 2017. accessdata.fda.gov Preservative-free formulation PI; relevant for patients with ocular surface sensitivity to benzalkonium chloride.
- Zimmerman TJ, Kaufman HE. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 1977;95(4):601–604. PMID: 322648. Landmark early clinical study establishing timolol as an effective IOP-lowering agent, forming the basis for FDA approval.
- Camras CB; United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial. Ophthalmology. 1996;103(1):138–147. PMID: 8628544. Pivotal comparative trial demonstrating equivalent IOP reduction between latanoprost QD and timolol 0.5% BID, establishing the benchmark against which prostaglandin analogues are measured.
- The Timolol-Pilocarpine Study Group. Timolol versus pilocarpine alone and combined: a three-year randomized trial. Ophthalmology. 1987;94(S):159. Long-term RCT comparing timolol monotherapy with pilocarpine, confirming sustained IOP efficacy and superior tolerability profile.
- European Glaucoma Society. Terminology and Guidelines for Glaucoma. 5th Edition. 2020. eugs.org Current EGS guidelines positioning beta-blockers as second-line agents after prostaglandin analogues for open-angle glaucoma.
- American Academy of Ophthalmology. Preferred Practice Pattern: Primary Open-Angle Glaucoma. 2020. aao.org US guideline recommending timolol as adjunctive or alternative first-line therapy when prostaglandins are contraindicated or poorly tolerated.
- Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure. In the normal eye. Arch Ophthalmol. 1978;96(11):2045–2048. PMID: 363105. Fluorophotometry study establishing that timolol lowers IOP primarily by reducing aqueous humour production rather than increasing outflow.
- Volotinen M, Mäenpää J, Pelkonen O, Uusitalo H. Metabolism of ophthalmic timolol: new aspects of an old drug. Basic Clin Pharmacol Toxicol. 2011;108(5):297–303. PMID: 21385322. Comprehensive review establishing CYP2D6 as the primary metabolising enzyme for timolol; discusses clinical implications of CYP2D6 polymorphisms.
- Korte JM, Kaila T, Saari KM. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefes Arch Clin Exp Ophthalmol. 2002;240(6):430–435. PMID: 12107508. Randomised crossover study quantifying ~78% systemic bioavailability of ophthalmic timolol, demonstrating cardiovascular effects comparable to IV administration.
- Nieminen T, Lehtimäki T, Mäenpää J, Ropo A, Uusitalo H, Kähönen M. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand J Clin Lab Invest. 2007;67(2):237–245. PMID: 17366003. Review of plasma PK and CYP2D6 polymorphism effects on timolol cardiopulmonary safety, including data on poor vs extensive metabolisers.
- Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kuritsky JN. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978–1985. Am J Ophthalmol. 1986;102(5):606–611. PMID: 3777080. FDA post-marketing surveillance review of serious systemic adverse events from ophthalmic timolol, documenting respiratory and cardiac deaths.
- Timolol. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Updated August 2024. ncbi.nlm.nih.gov Comprehensive reference covering timolol pharmacology, off-label uses (infantile haemangioma), PK parameters, and CYP2D6-related drug interactions.